Skip to content

Influencing factors of treatment outcomes in rifampicin-resistant patients

Influencing factors of treatment outcomes in rifampicin-resistant patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092976
Enrollment
Unknown
Registered
2024-11-26
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rifampicin-resistant tuberculosis

Interventions

Cure group:None

Sponsors

Jinan Municipal Center for Disease Control and Prevention
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Rifampicin resistant pulmonary tuberculosis patients diagnosed by provincial and municipal designated hospitals for tuberculosis; 2. Patients with rifampicin resistant pulmonary tuberculosis referred to the Drug Resistant Tuberculosis Department of the Provincial Public Health Clinical Center for full course treatment in 16 cities under Shandong Province; 3.The project patient should be a registered residence in Shandong Province, or provide the certificate of permanent resident population in Shandong Province or the certificate of temporary residence for more than 2 years;

Exclusion criteria

Exclusion criteria: 1.Individuals with consciousness and language barriers; 2.Other psychological or mental issues, the investigator believes that this survey will have a negative impact on the subject or that the subject's situation is not in line with the purpose of this survey;

Design outcomes

Primary

MeasureTime frame
cure;

Secondary

MeasureTime frame
Knowledge of tuberculosis core knowledge, nutrition and quality of life;

Countries

China

Contacts

Public ContactRan Xue

Jinan Municipal Center for Disease Control and Prevention

245159357@qq.com+86 531 81278897

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026